tiprankstipranks
Trending News
More News >
Hold Rating on Blueprint Medicines Amid Sanofi Acquisition and Market Uncertainties
PremiumRatingsHold Rating on Blueprint Medicines Amid Sanofi Acquisition and Market Uncertainties
20d ago
Apple downgraded, Snowflake upgraded: Wall Street’s top analyst calls
Premium
The Fly
Apple downgraded, Snowflake upgraded: Wall Street’s top analyst calls
21d ago
Blueprint Medicines upgraded to Neutral from Sell at Citi
Premium
The Fly
Blueprint Medicines upgraded to Neutral from Sell at Citi
21d ago
Blueprint Medicines downgraded to Hold from Buy at TD Cowen
PremiumThe FlyBlueprint Medicines downgraded to Hold from Buy at TD Cowen
23d ago
Blueprint downgraded to Peer Perform from Outperform at Wolfe Research
Premium
The Fly
Blueprint downgraded to Peer Perform from Outperform at Wolfe Research
23d ago
Blueprint Medicines downgraded to Neutral from Overweight at JPMorgan
Premium
The Fly
Blueprint Medicines downgraded to Neutral from Overweight at JPMorgan
23d ago
Blueprint Medicines downgraded to Neutral from Outperform at Wedbush
PremiumThe FlyBlueprint Medicines downgraded to Neutral from Outperform at Wedbush
23d ago
Sanofi acquisition of Blueprint Medicines ‘sensible,’ says BofA
Premium
The Fly
Sanofi acquisition of Blueprint Medicines ‘sensible,’ says BofA
23d ago
Sanofi’s Strategic Acquisition of Blueprint Medicines: A Buy Recommendation by Derek Archila
Premium
Ratings
Sanofi’s Strategic Acquisition of Blueprint Medicines: A Buy Recommendation by Derek Archila
23d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100